Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 5/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | GPR132 | Q9UNW8 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 2/20 | 0.50 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | KLK1 | P06870 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2998848 | 1.00 | F11 (0.65) | F11PRSS1PRSS2PRSS3CA2 | |
| SCHEMBL392725 | 0.79 | F11 (1.00) | F11PRSS1PRSS2PRSS3KLK1 | |
| SCHEMBL1281251 | 0.79 | F11 (1.00) | F11PRSS1PRSS2PRSS3KLK1 | |
| SCHEMBL1828604 | 0.79 | PTPN1 (0.56) | CA2CA1PTPN1GPR132ACE | |
| SCHEMBL7442309 | 0.76 | CA2 (0.71) | CA2CA1PTPN1GPR132ACE | |
| SCHEMBL7442291 | 0.76 | CA2 (0.71) | CA2CA1PTPN1GPR132ACE | |
| SCHEMBL6790346 | 0.76 | AGTR2 (0.56) | CA2CA1PTPN1GPR132ACE | |
| SCHEMBL6786437 | 0.76 | AGTR2 (0.56) | CA2CA1PTPN1GPR132ACE | |
| SCHEMBL528464 | 0.74 | ACE (0.76) | CA2CA1PTPN1GPR132ACE | |
| SCHEMBL111236 | 0.74 | ACE (0.76) | CA2CA1PTPN1GPR132ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152664-B1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8367709-B2 | Dipeptide analogs as coagulation factor inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-07-08 | — | — | US | disclosed |
| EP-2152664-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | Brystol-Myers Squibb Company (US) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008157162-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173899-A1 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS | F11, TFPI, SERPINC1 | F11 1/4885PRSS1 51/4885PRSS2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.